Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis

References

• Hossain MK, Nahar K, Donkor O, Apostolopoulos V. Immune-based therapies for metastatic prostate cancer: an update. Immunotherapy. 2018;10(4):283–298. doi:10.2217/imt-2017-012329421982
   PubMed Web of Science ®Google Scholar
• Ugurel S, Röhmel J, Ascierto P, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–257. doi:10.1016/j.ejca.2017.06.02828756137
   PubMed Web of Science ®Google Scholar
• Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy. 2016;8(3):279–298. doi:10.2217/imt.15.12326860624
   PubMed Web of Science ®Google Scholar
• Calabro L, Ceresoli GL, D‘Incecco A, Scherpereel A, Aerts J, Maio M. Immune checkpoint therapy of mesothelioma: pre-clinical bases and clinical evidences. Cytokine Growth Factor Rev. 2017;36:25–31. doi:10.1016/j.cytogfr.2017.07.00328736182
   PubMed Web of Science ®Google Scholar
• O‘Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110(12):2614–2627. doi:10.1002/cncr.2308618000991
   PubMed Web of Science ®Google Scholar
• Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol. 2010;37(5):485–498. doi:10.1053/j.seminoncol.2010.09.00321074064
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855. doi:10.1056/NEJMoa161129927717298
   PubMed Web of Science ®Google Scholar
• Hodi FS, O‘Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa100346620525992
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc323922437870
   PubMed Web of Science ®Google Scholar
• Shiuan E, Beckermann KE, Ozgun A, et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5:8. doi:10.1186/s40425-017-0210-028239462
   PubMed Web of Science ®Google Scholar
• Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793. doi:10.1136/bmj.k79329540345
   PubMed Web of Science ®Google Scholar
• Komaki Y, Komaki F, Yamada A, Micic D, Ido A, Sakuraba A. Meta‐analysis of the risk of immune‐related adverse events with anticytotoxic T‐lymphocyte‐associated antigen 4 and antiprogrammed death 1 therapies. Clin Pharmacol Ther. 2017;103(2):318–331.28118483
   PubMed Web of Science ®Google Scholar
• De Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312. doi:10.1158/2326-6066.CIR-16-023728246107
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13(1):211. doi:10.1186/s12916-015-0455-826337719
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b265119622551
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj Br Med J. 2011;343(7829):889–893. doi:10.1136/bmj.d5928
   Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83. doi:10.1093/annonc/mds21322858559
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046–2054. doi:10.1200/JCO.2011.38.403222547592
   PubMed Web of Science ®Google Scholar
• Maio M, Scherpereel A, Calabro L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261–1273. doi:10.1016/S1470-2045(17)30446-128729154
   PubMed Web of Science ®Google Scholar
• Govindan R, Szczesna A, Ahn MJ, et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017;35(30):3449–3457. doi:10.1200/JCO.2016.71.762928854067
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–47. doi:10.1200/JCO.2016.69.158428034081
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–3748. doi:10.1200/JCO.2016.67.660127458307
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712. doi:10.1016/S1470-2045(14)70189-524831977
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616–622. doi:10.1200/JCO.2012.44.611223295794
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi:10.1056/NEJMoa110462121639810
   PubMed Web of Science ®Google Scholar
• Weber J, Yang J, Atkins M, Disis M. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33(18):2092–2099. doi:10.1200/JCO.2014.60.037925918278
   PubMed Web of Science ®Google Scholar
• Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D. Ipilimumab-induced neutropenia in melanoma. J Investig Med High Impact Case Rep. 2016;4(3):2324709616661835. doi:10.1177/2324709616661835
   Google Scholar
• Meyers DE, Hill WF, Suo A, Jimenez-Zepeda V, Cheng T, Nixon NA. Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. Exp Hematol Oncol. 2018;7:6. doi:10.1186/s40164-018-0098-529568696
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Annals of the Rheumatic Diseases. 2016;76(1):43. doi:10.1136/annrheumdis-2016-20959527307501
   PubMed Web of Science ®Google Scholar
• Leipe J, Christ LA, Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 2018;4(2): e000714. doi: 10.1136/rmdopen-2018-000714
   Google Scholar
• Moslehi J, Salem J, Sosman J, Lebrun-Vignes B, Johnson D. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet (London, England). 2018;391(10124):933. doi:10.1016/S0140-6736(18)30302-7
   PubMed Web of Science ®Google Scholar
• Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. Bmj. 2014;349(nov21 3):g6501. doi:10.1136/bmj.g650125416499
   PubMed Web of Science ®Google Scholar
• Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(14):3977–3986. doi:10.1158/1078-0432.CCR-12-3243
   PubMed Web of Science ®Google Scholar